Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension

Cardiovascular Research

Volumn 104, Issue 1, 2014, Pages 37-48

  Rocchetti, Marcella ^a   Sala, Luca ^a   Rizzetto, Riccardo ^a   Irene Staszewsky, Lidia ^b   Alemanni, Matteo ^a   Zambelli, Vanessa ^a   Russo, Ilaria ^b   Barile, Lucio ^c   Cornaghi, Laura ^d   Altomare, Claudia ^a   Ronchi, Carlotta ^a   Mostacciuolo, Gaspare ^a   Lucchetti, Jacopo ^b   Gobbi, Marco ^b   Latini, Roberto ^b   Zaza, Antonio ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c DIVISION OF CARDIOLOGY   (Switzerland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Hypertrophy; Late sodium current; Pulmonary hypertension; Ranolazine; Remodelling

Indexed keywords

CALCIUM; COLLAGEN; MONOCROTALINE; MYOSIN HEAVY CHAIN; RANOLAZINE; SODIUM CALCIUM EXCHANGE PROTEIN; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE; SODIUM; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL DURATION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; CALCIUM TRANSPORT; CELLULAR HYPERTROPHY; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART RATE; HEART REPOLARIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HEMATOCRIT; HYPOXIA; IN VIVO STUDY; INCIDENCE; LUNG FLUID; LUNG VASCULAR RESISTANCE; MALE; MEMBRANE CURRENT; MUSCLE CELL; MUSCLE HYPERTROPHY; MYOCARDIAL DISEASE; MYOCARDIAL REMODELLING; MYOFIBROSIS; NONHUMAN; PLASMA VOLUME; POTASSIUM CURRENT; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SODIUM CURRENT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TRANSVERSE TUBULAR SYSTEM; UPREGULATION; WATER CONTENT; ANIMAL; CALCIUM SIGNALING; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HEART MUSCLE CELL; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MEMBRANE POTENTIAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; VASCULAR REMODELING; VASCULAR RESISTANCE;

ACETANILIDES; ANIMALS; CALCIUM SIGNALING; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MEMBRANE POTENTIALS; MONOCROTALINE; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; PIPERAZINES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SODIUM; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TIME FACTORS; VASCULAR REMODELING; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84913604100     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu188     Document Type: Article

References (33)

1. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032
2. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-1495
3. Hardziyenka M, Campian ME, Verkerk AO, Surie S, van Ginneken AC, Hakim S, Linnenbank AC, Bruin-Bon HA, Beekman L, van Der Plas MN, Remme CA, van Veen TA, Bresser P, de Bakker JM, Tan HL. Electrophysiologic remodeling of the left ventricle in pressure overload-induced right ventricular failure. J Am Coll Cardiol 2012;59:2193-2202
4. Lamberts RR, Vaessen RJ, Westerhof N, Stienen GJ. Right ventricular hypertrophy causes impairment of left ventricular diastolic function in the rat. Basic Res Cardiol 2007;102:19-27
5. Benoist D, Stones R, Drinkhill M, Bernus O, White E. Arrhythmogenic substrate in hearts of rats with monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2011;300:H2230-H2237
6. Benoist D, Stones R, Drinkhill MJ, Benson AP, Yang Z, Cassan C, Gilbert SH, Saint DA, Cazorla O, Steele DS, Bernus O, White E. Cardiac arrhythmia mechanisms in rats with heart failure induced by pulmonary hypertension. Am J Physiol Heart Circ Physiol 2012;302:H2381-H2395
7. Akhavein F, St Michel EJ, Seifert E, Rohlicek CV. Decreased left ventricular function, myocarditis, and coronary arteriolar medial thickening following monocrotaline administration in adult rats. J Appl Physiol 2007;103:287-295
8. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac late sodium current. Pharmacol Ther 2008;119:326-339
9. Moreno JD, Clancy CE. Pathophysiology of the cardiac lateNacurrent and its potential as a drug target. J Mol Cell Cardiol 2012;52:608-619
10. Zaza A, Rocchetti M. The late Na+ current-origin and pathophysiological relevance. Cardiovasc Drugs Ther 2013;27:61-68
11. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randles cycle. J Mol Med (Berl) 2012;90:31-43
12. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93:135-142
13. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007;321:213-220
14. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-910
15. Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol 2009;54: 279-286
16. Chemla D, Castelain V, Humbert M, Hebert JL, Simonneau G, Lecarpentier Y, Herve P. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004;126:1313-1317
17. Zaza A, Rocchetti M, Brioschi A, Cantadori A, Ferroni A. Dynamic Ca2+-induced inward rectification of K+ current during the ventricular action potential. Circ Res 1998;82: 947-956
18. Louch WE, Sejersted OM, Swift F. There goes the neighbourhood: pathological alterations in T-Tubule morphology and consequences for cardiomyocyte Ca2+ handling. J Biomed Biotechnol 2010;2010:503906
19. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC, Sabbah HN. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in Dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008;295:H2149-H2155
20. Correia-Pinto J, Henriques-Coelho T, Roncon-Albuquerque R Jr, Lourenco AP, Melo-Rocha G, Vasques-Novoa F, Gillebert TC, Leite-Moreira AF. Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotalineinduced pulmonary hypertension. Basic Res Cardiol 2009;104:535-545
21. Curran J, Brown KH, Santiago DJ, Pogwizd S, Bers DM, Shannon TR. Spontaneous Ca waves in ventricular myocytes from failing hearts depend on Ca(2+)-calmodulindependent protein kinase II. J Mol Cell Cardiol 2010;49:25-32
22. Swift F, Franzini-Armstrong C, Oyehaug L, Enger UH, Andersson KB, Christensen G, Sejersted OM, Louch WE. Extreme sarcoplasmic reticulum volume loss and compensatory T-Tubule remodeling after Serca2 knockout. Proc Natl Acad Sci USA 2012;109: 3997-4001
23. Aistrup GL, Gupta DK, Kelly JE, OToole MJ, Nahhas A, Chirayil N, Misener S, Beussink L, Singh N, Ng J, Reddy M, Mongkolrattanothai T, El Bizri N, Rajamani S, Shryock JC, Belardinelli L, Shah SJ, Wasserstrom JA. Inhibition of the late sodium current slows t-Tubule disruption During the progression of hypertensive heart disease in the rat. Am J Physiol Heart Circ Physiol 2013;305:H1068-H1079
24. Saeedi R, Grist M, Wambolt RB, Bescond-Jacquet A, Lucien A, Allard MF. Trimetazidine normalizes postischemic function of hypertrophied rat hearts. J Pharmacol Exp Ther 2005; 314:446-454
25. Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, ORourke B. Elevated cytosolic Na+decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res 2006;99:172-182
26. Deng CY, Kuang SJ, Rao F, Yang H, Fang XH, Shan ZX, Li XH, Zhou ZL, Lin QX, Yang M, Wu SL, Yu XY, Lin SG. Effect of ranolazine on rat intrarenal arteries in vitro. Eur J Pharmacol 2012;683:211-216
27. Paredes-Carbajal MC, Monsalvo I, Hernandez-Diaz C, Regla I, Demare P, Mascher D. Effects of ranolazine on vasomotor responses of rat aortic rings. Arch Med Res 2013; 44:8-12
28. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin) 2008; 2:449-460
29. Jo T, Nagata T, Iida H, Imuta H, Iwasawa K, Ma J, Hara K, Omata M, Nagai R, Takizawa H, Nagase T, Nakajima T. Voltage-gated sodium channel expressed in cultured human smooth muscle cells: involvement of SCN9A. FEBS Lett 2004;567:339-343
30. Platoshyn O, Remillard CV, Fantozzi I, Sison T, Yuan JX. Identification of functional voltage-gated Na(+) channels in cultured human pulmonary artery smooth muscle cells. Pflugers Arch 2005;451:380-387
31. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 2001;88:555-562
32. Lin MJ, Yang XR, Cao YN, Sham JS. Hydrogen peroxide-induced Ca2+ mobilization in pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2007;292: L1598-L1608
33. Sicouri S, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm 2013;10:1036-1043